

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A stent comprising:

a stent member having opposed inner and outer surfaces, such that said inner surface defines an aperture through the stent member;

a release layer, wherein the outer surface of said stent member is coated with the release layer; and

an insoluble fibrous component~~[[,]]~~ disposed around the outer surface of the stent member, so as to be releaseably carried by the release layer;

wherein ~~the insoluble fibrous component is wrapped around the stent, wherein the~~ insoluble fibrous component is released from the release layer and forms a reinforcing thrombus plug upon degradation of the release layer, and wherein the insoluble fibrous component is secured in place during implantation by the release layer, the release layer being designed to degrade only after implantation of the stent is complete.

2. (Original) The stent of claim 1, wherein the insoluble fibrous component comprises at least one nanofiber.

3. (Currently Amended) The stent of claim 1, wherein the insoluble fibrous component comprises a compound selected from the group consisting of poly(caprolactone), polyethylene terephthalate, fibrinogen, polyolefins, polyethylene, polypropylene, linear poly(ethylenimine), cellulose acetate, grafted cellulose, poly (L-lactic acid), poly (ethyleneoxide), poly (hydroxyethylmethacrylate), poly (glycolic acid) poly vinylpyrrolidone, polyethylene glycol, polyethylene oxazoline, polyester, polyacrylic acid, polyacrylic acid esters, polyphosphazines, polycyanoacrylate, polyvinyl amines, polyethylene imines, polyethylene amines, polyacrylamides, cellulose, polyorthoesters, polyanhydrides, polyketals, polyacetals, polyureas, and polycarbonate.

4. (Original) The stent of claim 1, wherein the insoluble fibrous component comprises a thrombogenic material that initiates the formation of a thrombus.

5. (Previously Presented) The stent of claim 4, wherein the thrombogenic material at least partially blocks the entrance to a structure selected from the group consisting of an aneurysm, a fistula, and an opening in a blood vessel wall.

6.-15. (Canceled)

16. (Previously Presented) A method for using the stent of claim 1, the method comprising the step of implanting the stent in a living organism.

17.-42. (Canceled)

43. (New) The stent of claim 1, wherein said insoluble fibrous component is wrapped around the outer surface of the stent member.